"Pfizer needs to overcome $17 billion in patent ex
Post# of 148181
(Total Views: 613)
Posted On: 01/10/2023 6:13:00 PM
"Pfizer needs to overcome $17 billion in patent expirations later this decade, Bourla acknowledged. From 2024 to 2027, Pfizer expects to lose U.S. exclusivity for popular blood thinner Eliquis, immunology med Xeljanz, rare disease med Vynadaqel, plus cancer drugs Ibrance, Inlyta and Xtandi. "
https://www.fiercepharma.com/pharma/jpm23-pfi...y-ceo-says
I have a modest suggestion......
https://www.fiercepharma.com/pharma/jpm23-pfi...y-ceo-says
I have a modest suggestion......
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼